top of page

What Are Autoimmune Diseases & How Do They Develop?

Autoimmune Diseases are caused when the immune system attacks its own cells. In this video, learn about autoimmunity, how autoimmune diseases develop and the symptoms they cause. Find out how autoimmune antibodies, B-cells and T-cells get made and how they get activated. Autoimmune cells are activated via molecular mimicry, bystander activation and epitope spreading. Persistent infections can increase the stimulation of the immune system over a person's lifetime and increase the chances of activating autoimmune cells. Watch the YouTube video or read on below to find out more.





What Are Autoimmune Diseases?


In autoimmune diseases, the body's immune system attacks the body's cells. This attack on the self by the immune system is called autoimmunity. There are more than a hundred autoimmune diseases. Some include Type 1 diabetes, Multiple Sclerosis, Lupus and Rheumatoid Arthritis. They can affect one organ, such as the pancreas in Type I Diabetes or the whole body, as in Lupus. 80% of all people diagnosed with autoimmune diseases are women. But it is unknown if this is due to hormones or genetic differences between men and women.


Autoimmune Diseases - Autoimmunity is when the immune system attacks the body'd cells. An illustrator drawing of a magnification of the pancreas to see a autoimmune T-cell killing pancreas cells. There is a ClevaLab logo in the corner.

What Is the Risk of Getting an Autoimmune Disease?


The risk of getting an autoimmune disease depends on genetics and environmental exposures. Environmental exposures include viruses, bacteria, diet and drugs. These exposures may be driving the increase in autoimmune diseases each year. Currently, autoimmune diseases affect 5 to 10% of people worldwide.


Symptoms of Autoimmune Diseases:


Symptoms experienced will depend on the type of autoimmune disease. For example, in rheumatoid arthritis, there is fatigue, joint stiffness, pain and swelling. In Multiple Sclerosis, there is fatigue, vision loss, and loss of balance.


Symptoms depend on the type of autoimmune disease. A anatomy illustrator drawing of some symptoms in rheumatoid arthritis. Fatigue, joint pain, joint swelling and joint stiffness. Also some symptoms of Multiple Sclerosis. Fatigue, vision loss and loss of balance. There is a ClevaLab logo in the corner.

How Are Autoimmune Diseases Diagnosed?


Diagnosis of autoimmune diseases involves looking at many factors. Some include symptoms, a full blood count, inflammatory markers, autoantibodies and MHC testing.


Autoantibodies are detectable in the blood years before the onset of symptoms. Yet, not all people with autoantibodies develop an autoimmune disease. For example, 10-45% of people have antinuclear antibodies, but not all go on to develop an autoimmune disease. Unfortunately, the genetic and environmental components that create an autoimmune disease remain unknown.


Autoimmunity - How Does It Happen?


Autoimmunity can result from both autoimmune antibodies and autoimmune T-cells. But a healthy person's immune system doesn't attack its tissues. This non-reactivity to self-tissues is immune tolerance. There are many checkpoints to remove self-antibodies and T-cells. But if these checkpoints fail, autoimmunity or loss of tolerance can occur.



So, where do things go wrong? First, let's look at how antibodies and T-cells get made. And also how autoantibodies and self-T-cells could emerge. Antibodies bind and neutralise pathogens or mark them for removal by the immune system. B-cells are the source of antibodies in the body. New B-cells arise from stem cells in the bone marrow. And it's in the bone marrow that the antibody the B-cell will make gets set. But, before leaving the bone marrow, B-cells get tested for autoreactivity. If they react to self-antigens, they die. If not, they move to the spleen. In the spleen, immature B-cells get exposed to self-antigens and die if they react. They then get released and move to the lymph nodes to await an infection. Autoreactive B-cells arise if there's an error at these self-antigen checkpoints.


This process of tolerance also happens for T-cells. A killer T-cell's job is to recognise foreign peptides on cell surfaces and kill the cells. A helper T-cell's job is to identify foreign peptides and help B-cells make antibodies. With the help of killer and helper T-cells, the body can fight infections both inside and outside of cells. T-cells originate from stem cells in the bone marrow. Then, they migrate to the thymus, where they mature. Here they get exposed to self-antigen, and any self-reactive T-cells will die. Some self-reactive T-cells can leave the thymus. But, a T-cell that recognises self-antigen without tissue inflammation will die.


How Are Autoreactive Cells Switched On?


Once autoreactive B and T-cells are present in the body, they can become activated in several ways. Some include molecular mimicry, bystander activation and epitope spreading.


Molecular mimicry is when a viral or bacterial peptide is like a self-peptide. A peptide is a short part of a protein. Shared peptides between viral and human proteins are high. So these shared peptides can activate self-B and T-cells to attack both virus and normal cells.


Activation of autoreactive T and B-cells by Molecular Mimicry. There is an illustrator drawing of a virus and a cell from the human body. There is a magnification to show that there is a peptide in common from the virus and a receptor on the cell. There's a ClevaLab logo in the corner.

But there must also be inflammation before B and T-cells can get activated. Dendritic cells, the sensing cells of the immune system, detect infections. Pathogens activate dendritic cells via their pattern recognition receptors. It is only activated dendritic cells that can trigger B and T-cells. But, tissue damage means that dendritic cells can also take up self-antigens. If the pattern recognition receptors also activate this dendritic cell. It can then activate autoimmune and viral B and T-cells. This activation of autoimmune cells is bystander activation.


Activation of Autorecative T and B-cells by bystander activation. There is an illustrator drawing of a dendritic cell taking up viral and self antigens that can activate viral and autoimmune cells. There's a ClevaLab logo in the corner.

The B-cell receptor is capable of binding and processing protein complexes. So it can internalise groups of proteins and show these to T-cells. The T-cell activating the B-cell doesn't need to match the same peptide as the B-cell. So a T-cell activated due to molecular mimicry can then activate B-cells producing other antibodies. So long as the original peptide is present in the complex. This spreading of antibodies can also happen within parts of the same protein. For example, let's take a cell surface receptor. Let's assume that there's an autoantibody for the internal part of the receptor. A B-cell can take in the whole receptor during tissue damage and present these as peptides to T-cells. Autoreactive T-cells targeting the outer part of the receptor then get activated. In turn, they can activate B-cells reactive to many other sites on the receptor. These antibodies can bind to the receptor always present and exposed to the immune system. Antibodies that bind the exposed proteins could lead to more prolonged inflammation. Epitope spread is the name given to this process. Epitope spreading leads to more inflammation and disease progression in autoimmune diseases. Autoimmune diseases likely develop due to more than one of these mechanisms.


Activation of autoreactive T and B-cells by epitope spread. There's an illustrator drawing of a B-cell that has bound a peptide complex and is being activated by a T-cell that recognises a different peptide. There's a ClevaLab logo in the corner.

Another possible contributor to developing an autoimmune disease is viral persistence. In some people, some viruses persist within cells, and the immune system cannot remove them. This constant activation of the immune system allows for more opportunities over a person's lifetime to activate an autoreactive T or B-cell.


Activation of autoreactive T and B-cells by viral persistence. There's a illustrator drawing of a human body showing a magnification to see the cells in the respiratory tract and a blood vessel. Persistent virus is seen in the nucleus of a respiratory epithelial lininig cell and a B-cell in the blood vessel. Viral persistence increases opportunity to turn on autoreactive T and B-cells. These's a CevaLab logo in the corner.

Autoimmune Disease Symptoms Depend on Their Target:


The symptoms caused by these autoreactive T-cells or autoantibodies depend on their target. A target present in only one organ, like in Type I Diabetes, will limit the damage to one organ, the pancreas. But if the target exists in many organs, as in Lupus, then autoantibodies can cause damage to many organs. In Lupus, the autoantibodies target proteins in the cell's nucleus. So Lupus can affect all cells of the body.


Autoimmune Disease symptoms depend on the target antigen. There's an illustrator drawing of two human bodies. One with a pancreas sowing one organ is affected in Type I Diabetes. The other body has a brain, heart, kidneys, lungs, and skin labelled showing that many organs are affected in Lupus. There's a ClevaLab logo in the corner.

Unfortunately, there is no cure for autoimmune diseases. While we know that viruses, bacteria, and genetics play a role, we don't know the exact cause of disease. So treatments focus on reducing symptoms and inflammation. Examples include immunosuppressants, steroids and NSAIDs. We need more research into why people develop autoimmune diseases. The development of targeted therapies depends on more knowledge about the causes.



References:


  1. Text Book for Immunology: Janeway's Immunobiology, 9th Edition, Kenneth Murphy & Casey Weaver.

  2. Good overall review of Autoimmune Diseases: Wang, L., Wang, F. S. & Gershwin, M. E. Human autoimmune diseases: A comprehensive update. J. Intern. Med.278, 369–395 (2015).

  3. Higher prevalence of Autoimmune Diseases in women: Angum, F., Khan, T., Kaler, J., Siddiqui, L. & Hussain, A. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus12, (2020).

  4. Increasing incidence of Autoimmune Disease: Lerner, A., Jeremias, P. & Matthias, T. The world incidence and prevalence of autoimmune diseases is increasing. Int. J. Celiac Dis.3, 151–155 (2015).

  5. Diagnostic Testing for Autoimmune Diseases: Castro, C. & Gourley, M. Diagnostic Testing and Interpretation of Tests for Autoimmunity. J Allergy Clin Immunol. 2010125, S238–S247 (2010).

  6. Rheumatoid Arthritis autoantibodies detected up to 14 yrs before onset of symptoms: Nielen, M. M. J. et al. Specific Autoantibodies Precede the Symptoms of Rheumatoid Arthritis: A Study of Serial Measurements in Blood Donors. Arthritis Rheum. 50, 380–386 (2004).

  7. Viruses and Autoimmunity: Smatti, M. K. et al. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses11, 762 (2019).

  8. There's a high level of shared peptides between viral and human proteins: Kanduc, D. The comparative biochemistry of viruses and humans: An evolutionary path towards autoimmunity. Biol. Chem.400, 629–638 (2019).

bottom of page